• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Oncternal Announces First Patient Dosed in Cirmtuzumab, Paclitaxel Trial americanpharmaceuticalreview
    September 13, 2018
    Oncternal Therapeutics announced the first patient has been dosed in a Phase 1b study of cirmtuzumab, an anti-ROR1 monoclonal, in combination with standard-of-care chemotherapy drug paclitaxel in patients with HER2/neu negative metastatic or locally advan

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service